Search hospitals > Delaware > Newark
Delaware Clinical and Laboratory Physicians PA
Claim this profileNewark, Delaware 19713
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
175 reported clinical trials
2 medical researchers
Summary
Delaware Clinical and Laboratory Physicians PA is a medical facility located in Newark, Delaware. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Delaware Clinical and Laboratory Physicians PA is involved with conducting 175 clinical trials across 344 conditions. There are 2 research doctors associated with this hospital, such as Gregory A. Masters and Mark E. Borowsky.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Gregory A. MastersHelen F Graham Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
123 reported clinical trials
201 drugs studied
Mark E. BorowskyJersey Shore Medical Center12 years of reported clinical research
Studies Serous Cystadenocarcinoma
Studies Adenocarcinoma
3 reported clinical trials
11 drugs studied
Clinical Trials running at Delaware Clinical and Laboratory Physicians PA
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Diffuse Large B-Cell Lymphoma
Anal Cancer
Squamous Cell Carcinoma
Lymphoma
Anal Squamous Cell Carcinoma
Gastroesophageal Junction Adenocarcinoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Whole Brain Radiotherapy + Stereotactic Radiosurgery
for Brain Metastasis
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is important for memory. The medicine memantine is also often given with whole brain radiation therapy because it may decrease the risk of side effects of radiation on thinking and memory. Stereotactic radiosurgery delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery may be effective in shrinking or stabilizing cancer that has spread to the brain and returned in other areas of the brain after receiving stereotactic radiosurgery.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Delaware Clinical and Laboratory Physicians PA?
Delaware Clinical and Laboratory Physicians PA is a medical facility located in Newark, Delaware. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Delaware Clinical and Laboratory Physicians PA is involved with conducting 175 clinical trials across 344 conditions. There are 2 research doctors associated with this hospital, such as Gregory A. Masters and Mark E. Borowsky.